Epilepsy is a chronic neurological disorder characterized by unpredictable seizures. Epilepsy is the fourth most common neurological disorder that affects peoples of all age group. Seizures may be classified as focal seizures, generalized seizures, and other seizures. Focal seizures are the most common type of epilepsy which involves secondary generalized tonic/clonic seizures (sGTCS) and complex partial seizures. Generalized seizures include myoclonic seizures, tonic seizures, atonic seizures, absences, and clonic seizures. These seizures occur when neurons in the brain or a group of nerve cells send wrong signals to the body.
Treatment of epilepsies is done by using antiepileptic drugs (AEDs). Antiepileptic drugs are segmented into two major categories namely first generation AEDs and second generation AEDs. Selection of drugs is done by prescribed depending upon the type of seizure, part of the brain involved in epilepsy, the age of the patient.
Request to Download Sample Report at https://www.zionmarketresearch.com/sample/epilepsy-therapeutics-market
Epilepsy therapeutic drug market is mostly driven by increasing the prevalence of neurological disorders and technological advancements across many countries. Moreover, increasing awareness about diagnostics and treatment of neurological disorders in global market also help in driving the epileptic market growth. Nonavailability of medical facilities in poor and developing countries can restrict or hinder the growth of the epileptic therapeutic market over the years. Conversely, the prescribing pattern of drugs that give preference to first generation AEDs over second generation AEDs is restraining the epilepsy therapeutics market. Nonetheless, ongoing research and development in the healthcare literacy rate are expected to open growth avenues for the market over the years.
The report covers forecast and analysis of the epileptic therapeutic market on a global and regional level. The study provides historic data of 2015 along with a forecast from 2016 to 2021 based on revenue (USD Million). To understand the competitive landscape in the market, an analysis of Porter’s Five Forces model for the epileptic therapeutic drug market has also been included in the study. The report also analyzes several driving and restraining factors and their impact on the market during the forecast period. The study encompasses a market attractiveness analysis, wherein type segments are benchmarked based on their market size, growth rate, and general attractiveness.
Inquire more before buying this report @ https://www.zionmarketresearch.com/inquiry/epilepsy-therapeutics-market
The report provides detailed segmentation of the epileptic therapeutic drug market based on the type and regional segment.
Geographically, the market has been segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Demand has been analyzed and forecast based on the current trends for the period of six years. North America & Europe were the leading regional segments of the epileptic therapeutic drug market due to the availability of the second generation antiepileptic drug.
Three new AEDs have been approved in the U.S. since 2012 including ezogabine/retigabine, perampanel and eslicarbazepine acetate. Ezogabine/retigabine and perampanel among these have new mechanism of action and thus it is capturing good amount of market share in the U.S. The epileptic therapeutic market is expected to witness the highest growth in the Asia-Pacific region in the coming years due to high prevalence of epilepsy in India and China, increasing health care infrastructure, incomes, and awareness.
Browse detail report @ https://www.zionmarketresearch.com/report/epilepsy-therapeutics-market
Key players in the epileptic therapeutic market include Abbott Laboratories, GlaxoSmithKline plc, Cephalon, Inc., Johnson & Johnson, Pfizer, Inc., Novartis AG, Sunovion Pharmaceuticals, Inc.., Valeant Pharmaceuticals International, Inc., Sanofi S.A. and Shire.